Samvardhana Motherson subsidiary approved to acquire 50.1% stake in Rotary for 500 crore rupees
Read more
Business Standard
business-standard.com

Samvardhana Motherson subsidiary approved to acquire 50.1% stake in Rotary for 500 crore rupees

A subsidiary of the auto component manufacturer Samvardhana Motherson International Ltd, namely Samvardhana Motherson Adsys Tech Ltd (SMAST), has received approval to purchase 50.1 percent of the equity capital of Rotary Connectors Pvt Ltd at an enterprise valuation of 500.4 crore rupees.

The Board of Directors of Samvardhana Motherson International approved the deal, which will be executed entirely in cash, according to regulatory filings as of Monday. The transaction is expected to be completed by the end of the 2026-2027 fiscal year.

After the completion of the deal, SMAST will own 50.1 percent of the equity capital of Rotary Connectors Pvt Ltd (RCPL), after which RCPL will become an indirect subsidiary of Samvardhana Motherson International. Meanwhile, the promoters of RCPL will retain 49.9 percent of the equity capital in the company.

According to regulatory documentation, the Board of Directors of Samvardhana Motherson International Ltd (SAMIL) reviewed and approved the acquisition of 50.1 percent of the equity capital in Rotary Connectors Pvt Ltd by Samvardhana Motherson Adsys Tech Ltd, which is a wholly-owned subsidiary of the company, from the existing shareholders of RCPL during its meeting today.

This strategic partnership aligns with the Motherson group's vision for diversification and expansion of its business in the aerospace and defense sectors, particularly in the field of electrical wiring and connection systems.

Rotary Connectors specializes in manufacturing military-grade circular connectors and connection solutions for diverse applications across various sectors, including the aerospace and defense industries.

Similar stories

Novartis India to Acquire 'Minipress' Trademark from Pfizer for 125 Billion Rupees
Read more
business-standard.com

Novartis India to Acquire 'Minipress' Trademark from Pfizer for 125 Billion Rupees

The Board of Directors of Novartis India Ltd has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA. The total value of the deal is estimated at approximately 125 billion Indian rupees.

According to regulatory filings, this transaction involves the purchase of trademarks registered in India, as well as certain related intellectual property rights, for a total amount of 125 billion rupees. The company has already signed an asset purchase agreement and trademark transfer documents with Pfizer Inc USA and Pfizer Products Inc USA, with the signing and closing of the deal scheduled for the same timeframe.

The company noted that the drug Minipress XL (containing prazosin) is primarily used in India for treating hypertension (high blood pressure) and managing urinary symptoms of benign prostatic hyperplasia (BPH).

Furthermore, the filing indicated that according to IQVIA MAT data for July 2026, Minipress XL generated revenue of 22.86 billion rupees and demonstrated a Compound Annual Growth Rate (CAGR) of 6.3 percent over the last four years.

In a separate application, Pfizer Ltd announced that it will cease marketing, distribution, and sales of Minipress XL starting Monday. This decision is due to Pfizer Inc USA's decision to discontinue the production of Minipress XL.

Popular